INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
发明人:
CHOI, HAN GON,최한곤,KIM, KYEONG SOO,김경수,JIN, SUNG GIU,진성규,KIM, DONG SHIK,김동식,YONG, CHUL SOON,용철순,KIM, JONG OH,김종오,OH, YU KYOUNG,오유경,CHOI, HAN GONKR,KIM, KYEONG SOOKR,JIN, SUNG GIUKR,KIM, DONG SHIKKR,YONG, CHUL SOONKR,KIM, JONG OHKR,OH, YU KYOUNGKR
申请号：
KR1020160067198
公开号：
KR1017786880000B1
申请日:
2016.05.31
申请国别(地区):
KR
年份:
2017
代理人:
摘要：
The present invention relates to a pharmaceutical combination preparation comprising two or more types of phosphodiesterase-5 (PDE-5) inhibitors. Specifically, the present invention relates to a combination preparation for treating erectile dysfunction comprising: tadalafil as a first active component, whose particle size is controlled, and which has excellent solubility and release rate by using a surfactant, is pharmaceutically stable, and has improved bioavailability； and as a second active component, one or more types of PDE-5 inhibitors selected from the group consisting of sildenafil, vardenafil, udenafil, rodenafil, mirodenafil, and avanafil. Due to having significantly improved solubility and release rate of the first active component, tadalafil, and comprising more than one types of PDE-5 inhibitors selected from the group consisting of sildenafil, vardenafil, udenafil, rodenafil, mirodenafil, and avanafil in a single administration form, the pharmaceutical combination preparation of the present invention shows superior effects in terms of an early onset time of effect, longer drug persistence, and significantly reduced occurrence of side effects, thereby creating a synergistic effect in the treatment of erectile dysfunction. Thus, the pharmaceutical combination preparation of the present invention can serve as an alternative to pre-existing single-component erectile dysfunction medications such as Viagra and Cialis, and can be beneficially used in the treatment and alleviation of erectile dysfunction.본 발명은 2종 이상의 포스포다이에스터라제―5(phosphodiesterase-5) 억제제를 포함하는 약제학적 복합제제에 관한 것으로, 보다 상세하게는 제1 활성성분으로서 타다라필의 입도를 조절하고 계면활성제를 사용함으로써 용해도 및 용출률이 우수하고 제제학적으로 안정하며, 생체이용률이 향상된 타다라필 및 제2 활성성분으로서 실데나필, 바데나필, 유데나필, 로데나필, 미로데나필 및 아바나필로 이루어진 군으로부터 선택되는 1종 이상의 PDE-5 억제제를 포함하는, 발기부전 치료용 복합제제에 관한 것이다.본 발명에 따른 2종 이상의 포스포다이에스터라제―5(phosphodiesterase-5) 억제제를 포함하는 약제학적 복합제제의 제1 활성성분으로서 사용되는 난용성 약물인 타다라필의 용해도 및 용출특성이 현저히 개선되고, 하나의 단일 투여형내에 타다라필과, 실데나필, 바데나필, 유데나필, 로데나필, 미로데나필 및 아바나필
